Breyanzi Approved as Second-Line Treatment for Large B-Cell Lymphoma
The expanded approval was based on data from the phase 3 TRANSFORM and phase 2 PILOT studies.
The expanded approval was based on data from the phase 3 TRANSFORM and phase 2 PILOT studies.
The accelerated approval was based on data from two phase 2 trials: the ROAR basket study and the NCI-MATCH Subprotocol H study.
VBI-1901 is an investigational bivalent eVLP vaccine immunotherapeutic candidate designed to target 2 highly immunogenic CMV antigens, gB and pp65.
ATX01 is a topical formulation of amitriptyline designed to directly inhibit pain signaling in the nerve fibers on the epidermis and dermis.
Updated findings from the UNITY-CLL trial continue to show a possible increased risk of death among patients who received Ukoniq.
The accelerated approval for Kymriah was based on data from the phase 2 ELARA trial.
The approval was based on data from the phase 3 AGILE trial.
Mirvetuximab soravtansine is an antibody-drug conjugate comprised of a FRα-binding antibody, a cleavable linker, and a potent tubulin-targeting agent.
The phase 3 study compared tiragolumab plus atezolizumab with placebo plus atezolizumab in adults with PD-L1 high locally advanced, unresectable or metastatic NSCLC.
In 2 minutes, the portable ATUSA system automatically scans the entire breast volume and provides 3D visualization of the breast tissue.